Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia
- 1 September 1986
- journal article
- research article
- Published by Elsevier BV in American Journal Of Medicine
- Vol. 81 (3), 387-394
- https://doi.org/10.1016/0002-9343(86)90287-1
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Prediction of response of acute nonlymphocytic leukaemia to therapy with ‘high dose’ cytosine arabinosideBritish Journal of Haematology, 1984
- High-dose cytosine arabinoside therapy for refractory leukemiaBlood, 1983
- High Dose Cytosine Arabinoside in the Management of Refractory Acute LeukaemiaScandinavian Journal of Haematology, 1982
- High dose cytosine arabinoside (HDARAC) in refractory acute leukemiaCancer, 1979
- Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative GroupBritish Journal of Haematology, 1976
- Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemiaCancer, 1975
- Drugs Five Years LaterAnnals of Internal Medicine, 1975
- Cytarabine for Acute Leukemia in AdultsArchives of Internal Medicine, 1974
- Cytidine Deaminase and the Development of Resistance to Arabinosyl CytosineNature New Biology, 1971
- Studies on drug resistance—II. Kinase patterns in P815 neoplasms sensitive and resistant to 1-β-d-arabinofuranosylcytosineBiochemical Pharmacology, 1970